Infections and Treatment Options.

is a genus of nonfermenting Gram-negative bacteria under order Although primarily isolated from respiratory tract of people with cystic fibrosis, spp. can cause a broad range of infections in hosts with other underlying conditions. Their rare occurrence and ever-changing taxonomy hinder defining their clinical features, risk factors for acquisition and adverse outcomes, and optimal treatment. spp. are intrinsically resistant to several antibiotics (e.g., most cephalosporins, aztreonam, and aminoglycosides), and are increasingly acquiring resistance to carbapenems. Carbapenem resistance is mainly caused by multidrug efflux pumps and metallo-β-lactamases, which are not expected to be overcome by new β-lactamase inhibitors. Among the other new antibiotics, cefiderocol, and eravacycline were used as salvage therapy for a limited number of patients with infections. In this article, we aim to give an overview of the antimicrobial resistance in species, highlighting the possible place of new antibiotics in their treatment.